Diagnostic tests that look for specific genetic or molecular characteristics may be the key to helping doctors decide which lung cancer treatments work best for patients, two studies released on Wednesday suggest.In one, researchers found AstraZeneca's ( AZN.L ) lung cancer pill Iressa, or gefitinib, worked far better than chemotherapy in people from East Asia whose tumors had specific mutations in genes for the epidermal growth factor receptor or EGFR
Dear readers! Please observe community rules and respect each other. We do not practice censorship. However, all offensive comments will be deleted, and their posters will be blocked.